Belite Bio Inc ADR BLTE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BLTE is a good fit for your portfolio.
News
-
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
-
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
-
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
-
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
-
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Trading Information
- Previous Close Price
- $34.48
- Day Range
- $33.85–36.48
- 52-Week Range
- $11.00–48.60
- Bid/Ask
- $35.80 / $36.50
- Market Cap
- $1.09 Bil
- Volume/Avg
- 9,713 / 42,156
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 20
- Website
- https://www.belitebio.com
Valuation
|
Metric
|
BLTE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 11.11 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BLTE
|
|---|---|
Quick Ratio | 24.50 |
Current Ratio | 24.76 |
Interest Coverage | −1,266.88 |
Quick Ratio
BLTE
Profitability
|
Metric
|
BLTE
|
|---|---|
Return on Assets (Normalized) | −46.81% |
Return on Equity (Normalized) | −50.45% |
Return on Invested Capital (Normalized) | −50.22% |
Return on Assets
BLTE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rwwtzdclb | Cxb | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pxpffxz | Gtgmfdn | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tbwpzmf | Qwnpjpb | $98.8 Bil | |
MRNA
| Moderna Inc | Rmctxsbfy | Vwskc | $38.8 Bil | |
ARGX
| argenx SE ADR | Fzsjwsbtk | Qjqj | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Psvkzpl | Bnzpw | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jtqwnct | Sfzvpm | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pkkpntkgq | Vnqmgy | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mjhjfxwyj | Mmhznf | $12.4 Bil | |
INCY
| Incyte Corp | Kdlytdj | Xzybxyd | $11.9 Bil |